Royalty Pharma PLC
RPRX
Company Profile
Business description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Contact
110 East 59th Street
New YorkNY10022
USAT: +1 212 883-0200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
89
Stocks News & Analysis
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,594.40 | 37.00 | 0.43% |
| CAC 40 | 7,732.44 | 22.69 | 0.29% |
| DAX 40 | 21,004.92 | 101.53 | 0.49% |
| Dow JONES (US) | 43,487.83 | 334.70 | 0.78% |
| FTSE 100 | 8,522.41 | 17.19 | 0.20% |
| HKSE | 19,925.81 | 341.75 | 1.75% |
| NASDAQ | 19,630.20 | 291.91 | 1.51% |
| Nikkei 225 | 38,902.50 | 451.04 | 1.17% |
| NZX 50 Index | 13,088.31 | 42.12 | -0.32% |
| S&P 500 | 5,996.66 | 59.32 | 1.00% |
| S&P/ASX 200 | 8,347.40 | 37.00 | 0.45% |
| SSE Composite Index | 3,244.38 | 2.56 | 0.08% |